Chia Tian Qing's TQB2102 Succeeds in Late-Stage HER2-Low Breast Cancer Study, mPFS 16.4 Months

Chia Tian Qing's TQB2102 met its endpoint in a late-stage study in HER2-low breast cancer, with a median progression-free survival of 16.4 months versus 5.5 months in the chemotherapy control group. The risk of disease progression or death fell by about 71%, and treatment-related interstitial lung disease occurred in 2.2% of patients. Results were presented at the 2026 ESMO annual meeting.